Search results for "Enzyme-Linked Immunospot Assay"

showing 3 items of 3 documents

Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Alloge…

2018

Enzyme-Linked Immunospot Assaymedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusHematopoietic stem cell transplantationCD8-Positive T-Lymphocytes030230 surgeryAntiviral Agents03 medical and health sciences0302 clinical medicineCorrespondencemedicineHumansImmunology and AllergyCytotoxic T cellbusiness.industryHematopoietic Stem Cell TransplantationAntiviral therapyCmv dnaemiamedicine.diseaseTransplant RecipientsInfectious DiseasesCytomegalovirus InfectionsImmunology030211 gastroenterology & hepatologyCytomegalovirus infectionsAllogeneic hematopoietic stem cell transplantEnzyme linked immunospot assaybusinessThe Journal of Infectious Diseases
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

T helper cell- and CD40-dependent germline IgM prevents chronic virus-induced demyelinating disease

2012

Generation of antiviral IgM is usually considered as a marker of a short-lived initial antibody response that is replaced by hypermutated and more-efficient IgG. However, once viruses have established a particular niche for their persistence (e.g., within the CNS), the immune system has to specifically mobilize a broad range of antimicrobial effectors to contain the pathogen in the long term. Infection of the CNS with the mouse hepatitis virus (MHV) provides a unique model situation in which the extent of inflammatory CNS disease is determined by the balance between antiviral immune control, viral replication, and immune-mediated damage. We show here that whereas antibody- or B cell-defici…

Central Nervous SystemEnzyme-Linked Immunospot AssayFluorescent Antibody TechniqueVirusMice03 medical and health sciences0302 clinical medicineImmune systemCytidine DeaminaseActivation-induced (cytidine) deaminaseDemyelinating diseasemedicineAnimalsCD40 Antigens030304 developmental biologyMice KnockoutAnalysis of VarianceB-LymphocytesMurine hepatitis virus0303 health sciencesMultidisciplinaryCD40biologyT-Lymphocytes Helper-InducerT helper cellBiological SciencesFlow Cytometrymedicine.diseaseVirology3. Good healthmedicine.anatomical_structureImmunoglobulin MViral replicationImmunologybiology.proteinAntibodyDemyelinating Diseases030215 immunologyProceedings of the National Academy of Sciences
researchProduct